GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipella Pharmaceuticals Inc (NAS:LIPO) » Definitions » Gross-Profit-to-Asset %

Lipella Pharmaceuticals (Lipella Pharmaceuticals) Gross-Profit-to-Asset % : -100.45% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Lipella Pharmaceuticals Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Lipella Pharmaceuticals's annualized Gross Profit for the quarter that ended in Mar. 2024 was $-3.37 Mil. Lipella Pharmaceuticals's average Total Assets over the quarter that ended in Mar. 2024 was $3.36 Mil. Therefore, Lipella Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was -100.45%.


Lipella Pharmaceuticals Gross-Profit-to-Asset % Historical Data

The historical data trend for Lipella Pharmaceuticals's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipella Pharmaceuticals Gross-Profit-to-Asset % Chart

Lipella Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
-1.47 -80.66 -59.37 -54.35

Lipella Pharmaceuticals Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.55 -104.43 -105.26 -0.62 -100.45

Competitive Comparison of Lipella Pharmaceuticals's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Lipella Pharmaceuticals's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipella Pharmaceuticals's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Lipella Pharmaceuticals's Gross-Profit-to-Asset % falls into.



Lipella Pharmaceuticals Gross-Profit-to-Asset % Calculation

Lipella Pharmaceuticals's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-2.589/( (5.95+3.577)/ 2 )
=-2.589/4.7635
=-54.35 %

Lipella Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-3.372/( (3.577+3.137)/ 2 )
=-3.372/3.357
=-100.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Lipella Pharmaceuticals Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Lipella Pharmaceuticals's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipella Pharmaceuticals (Lipella Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's lead product candidates include LP-10 and LP-310.
Executives
Lori Birder director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Daniel R Cohen director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
David S. Battleman director C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
Byong Kim director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Jonathan H Kaufman director, 10 percent owner, officer: See Remarks C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Ryan Pruchnic director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Douglas Johnston officer: Chief Financial Officer C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Michael B Chancellor director, 10 percent owner, officer: Chief Medical Officer C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Naoki Yoshimura director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208